Invitae Corporation (0JDB.L)

0.0035 +0.0032 (+1,066.67%) 收市：04:03PM BST

Invitae Corporation

1400 16th Street
San Francisco, CA 94103
United States
415 374 7782
https://www.invitae.com

版塊: 
行業: 
全職員工: 1,700

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Randal W. Scott Ph.D.	Co-Founder & Chairman of the Board	50k	無	1958
Mr. Kenneth D. Knight	President, CEO & Director	1.4M	無	1961
Mr. Thomas R. Brida	General Counsel, Chief Compliance Officer & Secretary	776.72k	無	1971
Ms. Ana J. Schrank	Chief Accounting Officer & CFO	無	無	1966
Dr. David B. Sholehvar M.D.	Chief Operating Officer	無	無	1968
Ms. Hoki Luk	Head of Investor Relations and Capital Markets & Corporate Development	無	無	1976
Ms. Shelly D. Guyer	Chief Sustainability Officer	430.44k	無	1960
Ms. Desarie French	Chief Talent Officer	無	無	無
Dr. W. Michael Korn M.D.	Chief Medical Officer	無	無	無
Mr. Robert Guigley	Chief Commercial Officer	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California. On February 13, 2024, Invitae Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey.

公司管治

截至 2024年4月1日 止，Invitae Corporation 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：5；董事會：10；股東權利：7；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。